申请人:Pennell M.K. Andrew
公开号:US20060106218A1
公开(公告)日:2006-05-18
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
所提供的化合物可作为 CCR1 受体的强效拮抗剂,并具有体内抗炎活性。这些化合物通常是芳基哌嗪衍生物,可用于药物组合物、治疗 CCR1 介导的疾病的方法,并可在鉴定竞争性 CCR1 拮抗剂的试验中用作对照。